Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.8M
-
Number of holders
-
143
-
Total 13F shares, excl. options
-
31.3M
-
Shares change
-
+376K
-
Total reported value, excl. options
-
$504M
-
Value change
-
+$4.14M
-
Put/Call ratio
-
0.97
-
Number of buys
-
66
-
Number of sells
-
-56
-
Price
-
$16.11
Significant Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q4 2019
176 filings reported holding CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2019.
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 143 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.3M shares
of 54.8M outstanding shares and own 57.1% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (4.66M shares), BlackRock Inc. (3.55M shares), RHO CAPITAL PARTNERS INC (3.19M shares), FARALLON CAPITAL MANAGEMENT LLC (2.3M shares), VANGUARD GROUP INC (2.17M shares), FIRST MANHATTAN CO (1.44M shares), Chescapmanager LLC (1.3M shares), STATE STREET CORP (1M shares), Carmignac Gestion (909K shares), and DISCIPLINED GROWTH INVESTORS INC /MN (839K shares).
This table shows the top 143 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.